Decitabine
Mixed Phenotype Acute Leukemia,T/Myeloid
Explore 3 assets in Mixed Phenotype Acute Leukemia,T/Myeloid →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04446130CT.gov Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mixed Phenotype Acute Leukemia,T/Myeloid
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | The First Affiliated Hospital of Soochow University | P3 | B · 60 |
| Sorafenib | M.D. Anderson Cancer Center | P2 | B |
| Dexasone | M.D. Anderson Cancer Center | P2 | B |
| Idarubicin | M.D. Anderson Cancer Center | P2 | B |
| Rituximab | M.D. Anderson Cancer Center | P2 | B |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | B |
| Clofarabine | M.D. Anderson Cancer Center | P2 | B |
| (+)-Vincristine | M.D. Anderson Cancer Center | P2 | B |
| Cytarabine | yuejun Liu | P2 | B |
+2 more in the Mixed Phenotype Acute Leukemia,T/Myeloid cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Mixed Phenotype Acute Leukemia,T/Myeloid. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-mixed-phenotype-acute-leukemiatmyeloid
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →